

## Pritumumab

<b>Cat. No.:</b>	HY-P99806
<b>CAS No.:</b>	499212-74-7
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research <sup>[1][2]</sup> .
<b>In Vivo</b>	Pritumumab is effective in preventing tumor growth in nude mice but not in SCID mice <sup>[1]</sup> . Pritumumab can limit the growth of xenograft glioma tumors in vivo only in the presence of intact cell-mediated immunity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017.

[2]. Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human x human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA